Hepatorenal syndrome, MELD score and liver transplantation: An evolving issue with relevant implications for clinical practice

Journal of Hepatology

Volumn 57, Issue 5, 2012, Pages 1135-1140

  Angeli, Paolo ^a   Gines, Pere ^b,c  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF BARCELONA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Acute kidney injury; Albumin; Ascites; Cirrhosis; Combined liver kidney transplantation; Hepatorenal syndrome; Liver transplantation; MELD; Renal replacement therapy; Terlipressin

Indexed keywords

ALBUMIN; TERLIPRESSIN;

ARTICLE; CLINICAL PRACTICE; CREATININE BLOOD LEVEL; HEPATORENAL SYNDROME; HUMAN; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MORTALITY; PRIORITY JOURNAL; SODIUM BLOOD LEVEL;

EID: 84867572412     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.06.024     Document Type: Note

References (38)

1. P. Ginès, and R.W. Schrier Renal failure in cirrhosis New Engl J Med 361 2009 1279 1290
2. P. Angeli, and C. Merkel Pathogenesis and management of hepatorenal syndrome J Hepatol 48 2008 S93 S103
3. F. Salerno, A. Gerbes, P. Gines, F. Wong, and V. Arroyo Diagnosis, prevention and treatment of the hepatorenal syndrome in cirrhosis. A consensus workshop of the International Ascites Club Gut 56 2007 1310 1318
4. M. Guevara, P. Ginès, G. Fernández-Esparrach, P. Sort, J.M. Salmerón, and W. Jiménez Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion Hepatology 27 1998 35 41
5. P. Angeli, R. Volpin, G. Gerunda, R. Craighero, P. Roner, and R. Merenda Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide Hepatology 29 1999 1690 1697
6. C. Duvoux, D. Zanditenas, C. Hézode, A. Chauvat, J.L. Monin, and F. Roudot-Thoraval Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study Hepatology 36 2002 374 380
7. P. Sharma, A. Kumar, B.C. Shrama, and S.K. Sarin An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response Am J Gastroenterol 103 2008 1689 1697
8. K.A. Bresing, J. Textor, J. Perz, P. Schiedermaier, P. Raab, and H. Strunk Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome; a phase II study Gut 47 2000 288 295
9. S.R. Mitzener, J. Stange, S. Klammt, T. Risler, C.M. Erley, and B.D. Bader Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results on a prospective, randomized controlled clinical trial Liver Transpl 6 2000 277 286
10. M. Martín-Llahí, M.N. Pépin, M. Guevara, F. Díaz, A. Torre, and A. Monescillo Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study Gastroenterology 134 2008 1352 1359
11. A.J. Sanyal, T. Boyer, G. Garcia-Tsao, F. Regenstein, L. Rossaro, and B. Appenrodt A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome Gastroenterology 134 2008 1360 1368
12. L.L. Gluud, K. Christensen, E. Christensen, and A. Krag Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome Hepatology 51 2010 576 584
13. P. Ginès, P. Angeli, K. Lenz, S. Moller, K. Moore, and R. Moreau EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis J Hepatol 53 2010 397 417
14. A. Nazar, G.H. Pereira, M. Guevara, M. Martín-Llahi, M.N. Pepin, and M. Marinelli Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 HRS Hepatology 51 2010 219 226
15. T.D. Boyer, A.J. Sanyal, G. Garcia-Tsao, A. Blei, D. Carl, and A.S. Bexon Predictors of response to terlipressin plus albumin in hepatorenal syndrome [HRS] type 1: relationship of serum creatinine to hemodynamics J Hepatol 55 2011 315 321
16. P. Gines Pharmacological management of hepatorenal syndrome. Lessons from nonresponders J Hepatol 55 2011 268 269
17. P. Angeli, S. Fasolato, M. Cavallin, A. Trotta, G. Maresio, and A. Callegaro Terlipressin given as continuous intravenous infusion is the more suitable schedule for the treatment of type 1 hepatorenal syndrome [HRS] in patients with cirrhosis: results of a controlled clinical study Hepatology 48 2008 378A [Abstract]
18. K. Rifai, A. Kribben, G. Gerken, S. Haag, S. Herget-Rosenthal, and U. Treichel Extracorporeal liver support by fractionated plasma separation and adsorption [Prometheus] in patients with acute-on-chronic liver failure [HELIOS Study]: a prospective randomized controlled multicenter study J Hepatol 52 2010 S3 [Abstract]
19. R.B. Freeman, R.H. Wiesner, A. Harper, S.V. McDiarmid, J. Lake, and E. Edwards The new liver allocation system: moving toward evidence-based transplantation policy Liver Transpl 8 2002 851 858
20. M. Bernardi, S. Gitto, and M. Biselli The MELD score in patients awaiting liver transplant: strengths and weaknesses J Hepatol 54 2011 1297 1306
21. C. Francoz, J. Belghiti, D. Castaing, O. Chazouillères, J.C. Duclos-Vallée, and C. Duvoux MELD exceptions in the context of the MELD score-based French Liver Int 17 2011 1137 1151
22. R.B. Freeman Jr., R.G. Gish, A. Harper, G.L. Davis, J. Vierling, and L. Lieblein Model for end-stage liver disease [MELD] exception guidelines: results and recommendations from the MELD Exception Study Group and Conference [MESSAGE] for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula Liver Transpl 12 2006 S128 S136
23. C. Alessandria, O. Ozdogan, M. Guevara, T. Restuccia, W. Jiménez, and V. Arroyo MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation Hepatology 41 2005 1282 1289
24. M. Martín-Llahí, M. Guevara, A. Torre, C. Fagundes, T. Restuccia, and R. Gilabert Prognostic importance of the cause of renal failure in patients with cirrhosis Gastroenterology 40 2011 488 496
25. K. Washburn MELD exceptions: proceed with caution Liver Transpl 2011 [Epub ahead of print]
26. European Association for the Study of the Liver EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis J Hepatol 53 2010 397 417
27. T. Restuccia, R. Ortega, M. Guevara, P. Ginès, C. Alessandria, and O. Ozdogan Effects of treatment of hepatorenal syndrome before transplantation on post transplantation outcome. A case-control study J Hepatol 40 2004 140 146
28. P. Caraceni, L. Santi, F. Mirici, G. Montanari, G. Bevilacqua, and AD. Pinna Long-term treatment of hepatorenal syndrome as a bridge to liver transplantation Dig Liver Dis 43 2011 242 245
29. S. Piano, F. Morando, S. Fasolato, M. Cavallin, N. Boscato, and P. Boccagni Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: a new exception to the MELD score in the allocation system to liver transplantation? J Hepatol 55 2011 491 496
30. T.D. Boyer, A.J. Sanyal, G. Garcia-Tsao, F. Regenstein, L. Rossaro, and B. Appenrodt Impact of liver transplantation on survival of patients treated for type 1 hepatorenal syndrome [HRS-1] Liver Transpl 17 2011 1328 1332
31. C. Alessandria, A. Ottobrelli, W. Debernardi-Venon, L. Todros, M.T. Cerenzia, and S. Martini Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study J Hepatol 47 2007 499 505
32. Nadim MK, Genyk YS, Tokin C, Fieber J, Ananthapanyasut W, Ye W, et al. Impact of etiology of acute kidney injury on outcomes following liver transplantation: acute tubular necrosis versus hepatorenal syndrome. Liver Transpl 2012 Jan 17. http://dx.doi.org/10.1002/lt.23384 [Epub ahead of print].
33. J.P. Rice, C. Skagen, and A. Said Liver transplant outcomes for patients with hepatorenal syndrome treated with pretransplant vasoconstrictors and albumin Transplantation 91 2011 1141 1147
34. P.E. Marik, K. Wood, and T.E. Starzl The course of type 1 hepato-renal syndrome post liver transplantation Nephrol Dial Transplant 21 2006 478 482
35. X. Xu, Q. Ling, M. Zhang, F. Gao, Z. He, and J. You Outcome of patients with hepatorenal syndrome type 1 after liver transplantation: Hangzhou experience Transplantation 87 2009 1514 1519
36. C.L. Davies, S. Feng, R. Sung, F. Wong, N.P. Goodrich, and L.B. Melton Simultaneous liver-kidney transplantation: evaluation to decision making Am J Transplant 7 2007 1702 1709
37. J.D. Eason, T.A. Gonwa, C.L. Davies, R.S. Sung, D. Gerber, and R.D. Bloom Proceedings of consensus conference on simultaneous liver-kidney transplantation [SLK] Am J Transplant 8 2008 2243 2251
38. M.R. Charlton, W.J. Wall, A.O. Ojo, P. Ginès, S. Textor, and F.S. Shihab Report of the first International Liver Transplantation Society Expert Panel Consensus Conference on renal insufficiency in liver transplantation Liver Transpl 15 2009 S1 S34